GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine

Janos P. Kiss, Bernadett K. Szasz, László Fodor, A. Mike, Nora Lenkey, Dalma Kurkó, József Nagy, E. Vízi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Accumulating evidence has indicated the involvement of glutamatergic neurotransmission in the pathophysiology of excitotoxicity and in the mechanism of action of antidepressants. We have previously shown that tricyclic desipramine and the selective serotonin reuptake inhibitor fluoxetine inhibit NMDA receptors (NMDARs) in the clinically relevant, low micromolar concentration range. As the different subtypes of NMDARs are markedly different in their physiological and pathological functions, our aim was to investigate whether the effect of antidepressants is subtype-specific. Using whole-cell patch-clamp recordings in rat cortical cell cultures, we studied the age-dependence of inhibition of NMDA-induced currents after treatment with desipramine and fluoxetine, as the expression profile of the NMDAR subtypes changes as a function of days in vitro. We also investigated the inhibitory effect of these antidepressants on NMDA-induced currents in HEK 293 cell lines that stably expressed rat recombinant NMDARs with GluN1a/GluN2A or GluN1a/GluN2B subunit compositions. The inhibitory effect of desipramine was not age-dependent, whereas fluoxetine displayed a continuously decreasing inhibitory profile, which was similar to the GluN1/GluN2B subtype-selective antagonist ifenprodil. In HEK 293 cells, desipramine equally inhibited NMDA currents in both cell lines, whereas fluoxetine showed an inhibitory effect only in cells that expressed the GluN1/GluN2B subtype. Our data show that fluoxetine is a selective inhibitor of GluN2B-containing NMDARs, whereas desipramine inhibits both GluN1/GluN2A and GluN1/GluN2B subtypes. As the clinical efficacy of these drugs is very similar, the putative NMDAR-associated therapeutic effect of antidepressants may be mediated only via inhibition of the GluN2B-containing subtype. The manifestation of the GluN1/GluN2B-selectivity of fluoxetine suggests the neuroprotective potential for this drug in both acute and chronic neurodegenerative disorders.

Original languageEnglish
Pages (from-to)170-176
Number of pages7
JournalNeurochemistry International
Volume60
Issue number2
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Fluoxetine
Neuroprotective Agents
N-Methyl-D-Aspartate Receptors
Desipramine
Antidepressive Agents
N-Methylaspartate
HEK293 Cells
Serotonin Uptake Inhibitors
Therapeutic Uses
Synaptic Transmission
Neurodegenerative Diseases
Cell Culture Techniques
Cell Line
Pharmaceutical Preparations

Keywords

  • Depression
  • Desipramine
  • Fluoxetine
  • GluN2B subunit
  • Neuroprotection
  • NMDA receptor subtypes
  • Whole-cell patch-clamp

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. / Kiss, Janos P.; Szasz, Bernadett K.; Fodor, László; Mike, A.; Lenkey, Nora; Kurkó, Dalma; Nagy, József; Vízi, E.

In: Neurochemistry International, Vol. 60, No. 2, 01.2012, p. 170-176.

Research output: Contribution to journalArticle

Kiss, Janos P. ; Szasz, Bernadett K. ; Fodor, László ; Mike, A. ; Lenkey, Nora ; Kurkó, Dalma ; Nagy, József ; Vízi, E. / GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine. In: Neurochemistry International. 2012 ; Vol. 60, No. 2. pp. 170-176.
@article{ea9cebab2aa444148baf68bb1944f7e5,
title = "GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine",
abstract = "Accumulating evidence has indicated the involvement of glutamatergic neurotransmission in the pathophysiology of excitotoxicity and in the mechanism of action of antidepressants. We have previously shown that tricyclic desipramine and the selective serotonin reuptake inhibitor fluoxetine inhibit NMDA receptors (NMDARs) in the clinically relevant, low micromolar concentration range. As the different subtypes of NMDARs are markedly different in their physiological and pathological functions, our aim was to investigate whether the effect of antidepressants is subtype-specific. Using whole-cell patch-clamp recordings in rat cortical cell cultures, we studied the age-dependence of inhibition of NMDA-induced currents after treatment with desipramine and fluoxetine, as the expression profile of the NMDAR subtypes changes as a function of days in vitro. We also investigated the inhibitory effect of these antidepressants on NMDA-induced currents in HEK 293 cell lines that stably expressed rat recombinant NMDARs with GluN1a/GluN2A or GluN1a/GluN2B subunit compositions. The inhibitory effect of desipramine was not age-dependent, whereas fluoxetine displayed a continuously decreasing inhibitory profile, which was similar to the GluN1/GluN2B subtype-selective antagonist ifenprodil. In HEK 293 cells, desipramine equally inhibited NMDA currents in both cell lines, whereas fluoxetine showed an inhibitory effect only in cells that expressed the GluN1/GluN2B subtype. Our data show that fluoxetine is a selective inhibitor of GluN2B-containing NMDARs, whereas desipramine inhibits both GluN1/GluN2A and GluN1/GluN2B subtypes. As the clinical efficacy of these drugs is very similar, the putative NMDAR-associated therapeutic effect of antidepressants may be mediated only via inhibition of the GluN2B-containing subtype. The manifestation of the GluN1/GluN2B-selectivity of fluoxetine suggests the neuroprotective potential for this drug in both acute and chronic neurodegenerative disorders.",
keywords = "Depression, Desipramine, Fluoxetine, GluN2B subunit, Neuroprotection, NMDA receptor subtypes, Whole-cell patch-clamp",
author = "Kiss, {Janos P.} and Szasz, {Bernadett K.} and L{\'a}szl{\'o} Fodor and A. Mike and Nora Lenkey and Dalma Kurk{\'o} and J{\'o}zsef Nagy and E. V{\'i}zi",
year = "2012",
month = "1",
doi = "10.1016/j.neuint.2011.12.005",
language = "English",
volume = "60",
pages = "170--176",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - GluN2B-containing NMDA receptors as possible targets for the neuroprotective and antidepressant effects of fluoxetine

AU - Kiss, Janos P.

AU - Szasz, Bernadett K.

AU - Fodor, László

AU - Mike, A.

AU - Lenkey, Nora

AU - Kurkó, Dalma

AU - Nagy, József

AU - Vízi, E.

PY - 2012/1

Y1 - 2012/1

N2 - Accumulating evidence has indicated the involvement of glutamatergic neurotransmission in the pathophysiology of excitotoxicity and in the mechanism of action of antidepressants. We have previously shown that tricyclic desipramine and the selective serotonin reuptake inhibitor fluoxetine inhibit NMDA receptors (NMDARs) in the clinically relevant, low micromolar concentration range. As the different subtypes of NMDARs are markedly different in their physiological and pathological functions, our aim was to investigate whether the effect of antidepressants is subtype-specific. Using whole-cell patch-clamp recordings in rat cortical cell cultures, we studied the age-dependence of inhibition of NMDA-induced currents after treatment with desipramine and fluoxetine, as the expression profile of the NMDAR subtypes changes as a function of days in vitro. We also investigated the inhibitory effect of these antidepressants on NMDA-induced currents in HEK 293 cell lines that stably expressed rat recombinant NMDARs with GluN1a/GluN2A or GluN1a/GluN2B subunit compositions. The inhibitory effect of desipramine was not age-dependent, whereas fluoxetine displayed a continuously decreasing inhibitory profile, which was similar to the GluN1/GluN2B subtype-selective antagonist ifenprodil. In HEK 293 cells, desipramine equally inhibited NMDA currents in both cell lines, whereas fluoxetine showed an inhibitory effect only in cells that expressed the GluN1/GluN2B subtype. Our data show that fluoxetine is a selective inhibitor of GluN2B-containing NMDARs, whereas desipramine inhibits both GluN1/GluN2A and GluN1/GluN2B subtypes. As the clinical efficacy of these drugs is very similar, the putative NMDAR-associated therapeutic effect of antidepressants may be mediated only via inhibition of the GluN2B-containing subtype. The manifestation of the GluN1/GluN2B-selectivity of fluoxetine suggests the neuroprotective potential for this drug in both acute and chronic neurodegenerative disorders.

AB - Accumulating evidence has indicated the involvement of glutamatergic neurotransmission in the pathophysiology of excitotoxicity and in the mechanism of action of antidepressants. We have previously shown that tricyclic desipramine and the selective serotonin reuptake inhibitor fluoxetine inhibit NMDA receptors (NMDARs) in the clinically relevant, low micromolar concentration range. As the different subtypes of NMDARs are markedly different in their physiological and pathological functions, our aim was to investigate whether the effect of antidepressants is subtype-specific. Using whole-cell patch-clamp recordings in rat cortical cell cultures, we studied the age-dependence of inhibition of NMDA-induced currents after treatment with desipramine and fluoxetine, as the expression profile of the NMDAR subtypes changes as a function of days in vitro. We also investigated the inhibitory effect of these antidepressants on NMDA-induced currents in HEK 293 cell lines that stably expressed rat recombinant NMDARs with GluN1a/GluN2A or GluN1a/GluN2B subunit compositions. The inhibitory effect of desipramine was not age-dependent, whereas fluoxetine displayed a continuously decreasing inhibitory profile, which was similar to the GluN1/GluN2B subtype-selective antagonist ifenprodil. In HEK 293 cells, desipramine equally inhibited NMDA currents in both cell lines, whereas fluoxetine showed an inhibitory effect only in cells that expressed the GluN1/GluN2B subtype. Our data show that fluoxetine is a selective inhibitor of GluN2B-containing NMDARs, whereas desipramine inhibits both GluN1/GluN2A and GluN1/GluN2B subtypes. As the clinical efficacy of these drugs is very similar, the putative NMDAR-associated therapeutic effect of antidepressants may be mediated only via inhibition of the GluN2B-containing subtype. The manifestation of the GluN1/GluN2B-selectivity of fluoxetine suggests the neuroprotective potential for this drug in both acute and chronic neurodegenerative disorders.

KW - Depression

KW - Desipramine

KW - Fluoxetine

KW - GluN2B subunit

KW - Neuroprotection

KW - NMDA receptor subtypes

KW - Whole-cell patch-clamp

UR - http://www.scopus.com/inward/record.url?scp=84855261952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855261952&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2011.12.005

DO - 10.1016/j.neuint.2011.12.005

M3 - Article

C2 - 22197911

AN - SCOPUS:84855261952

VL - 60

SP - 170

EP - 176

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 2

ER -